How should progesterone intolerance be managed, including discontinuation of the offending preparation and selection of alternative hormonal or non‑hormonal therapies?

Management of Progesterone Intolerance

When progesterone intolerance occurs, immediately discontinue the offending preparation and switch to micronized progesterone or dydrogesterone, which demonstrate superior tolerance profiles and minimal systemic side effects compared to synthetic progestogens. 1, 2

Understanding Progesterone Intolerance

Progesterone intolerance manifests through multiple mechanisms that significantly impact compliance with hormone therapy:

• Endometrial effects vary between individuals and different progestogens, leading to problematic bleeding patterns 1
• Fluid retention symptoms result from sodium-retaining effects on the renin-aldosterone system 1
• Metabolic adverse effects occur with nor-testosterone-derived progestogens, including negative impacts on skin, lipids, vasculature, and insulin resistance 1
• Negative mood effects are produced by most progestogens through effects on neurotransmitters via central nervous system progesterone receptors 1

Immediate Management: Discontinuation Protocol

If serious adverse events occur (stroke, venous thromboembolism, myocardial infarction, or suspected breast malignancy), discontinue estrogen plus progestin therapy immediately. 3

• For less severe intolerance symptoms, discontinue the current progestogen preparation and reassess the patient's symptoms 1
• Symptomatic treatment should be provided as needed in cases of overdosage 3

Selection of Alternative Progestogen Preparations

First-Line Alternatives: Progesterone Receptor-Specific Options

Micronized progesterone and dydrogesterone are the safest progestogens with acceptable metabolic profiles and should be prioritized when switching from synthetic progestogens. 2, 4

• These preparations demonstrate favorable outcomes without deleterious effects in clinical studies of postmenopausal women 4
• Progesterone prevents endometrial hyperplasia while relieving vasomotor symptoms and improving quality-of-life measures 4
• Risk of venous thromboembolism and breast cancer does not appear to increase with progesterone plus estrogens, unlike synthetic progestins 4
• No detrimental effects on cardiovascular disease or cognition outcomes have been found with progesterone in hormone therapy 4

Alternative Progestogen Classes

When micronized progesterone is not suitable, consider progesterone receptor-specific progestogens:

• Pregnanes (e.g., cyproterone acetate) minimize adverse effects compared to nor-testosterone derivatives 1
• Nor-pregnanes (e.g., nomegestrol acetate) provide a more favorable hormonal profile 5
• These alternatives avoid the androgenic side effects associated with nor-testosterone-derived progestogens 1

Dosing and Administration Strategies to Improve Tolerance

Manipulation of Progestogen Regimen

• Reduce the dosage and duration of progestogen administration to minimize side effects 1
• Continuous administration of low-dose progestogen rather than sequential regimens can improve tolerance 1
• Reduce the number of progestogenic episodes to decrease cumulative exposure and side effects 1

Route of Administration Modifications

Local delivery systems minimize systemic side effects and should be considered for severely progestogen-intolerant women:

• Levonorgestrel intrauterine device minimizes systemic progestogen absorption, though some systemic levels do occur 6
• Vaginal progesterone gel provides endometrial protection while minimizing systemic exposure 1
• Transdermal, vaginal, or intrauterine administration routes can be used as alternatives to oral progestogen 6

Non-Hormonal Alternatives

For Women Unable to Tolerate Any Progestogen

• Conjugated equine estrogens combined with bazedoxifene (CEE/BZA) provides an alternative to progestogen therapy for women with a uterus who are averse to vaginal bleeding, breast tenderness, or altered mood 6
• This combination relieves vasomotor symptoms and vaginal atrophy while reducing bone resorption without requiring progestogen 6
• The approved dose is CEE 0.45 mg/bazedoxifene 20 mg, evaluated in randomized controlled trials up to 2 years duration 6

Definitive Surgical Option

• Hysterectomy remains an option for severely progestogen-intolerant women who cannot tolerate any alternative preparation 1
• Following hysterectomy, estrogen-alone therapy can be used without progestogen 6

Monitoring and Follow-Up

• Monthly clinic visits during the first 3 months are advised to assess mood, anxiety, and irritability when initiating new progestogen preparations 5
• Monitor for irregular bleeding, which is common in the first 3–6 months and generally not harmful 5
• Weight monitoring is important as weight changes can affect hormonal therapy efficacy 5

Critical Caveats

• Avoid custom-compounded hormone therapies as they lack FDA oversight and have no clinical trials documenting efficacy and safety for endometrial protection 6
• Use only FDA-approved preparations that are biochemically identical to endogenous hormones 6
• Do not measure salivary hormone levels to monitor therapy due to lack of scientific evidence and significant variability 6
• Progestogen therapy should be avoided in women with breast cancer except under limited circumstances, as the effect on recurrence is unclear 6